Vicor Technologies, Inc. (OTCBB: VCRT)
LEVEL 1 TRADE IDEA
Dear Members,
First - Welcome to 2010!
Vicor has been here for some time. (In the furture with cutting edge technology that will save lives.) I think they will be one of the key stocks we follow this year.
In a Biotech company evaluation it is crucial to understand their evolutionary process.
One of the many things I like about Vicor is that they have been extremely business savvy – not JUST in terms of their business model but in terms of their timing.
Vicor has used a stair stepped approach. They are rolling out their products in very effective layers.
Their first roll out is virtually underway with products in a limited number of physician offices. This will allow them to manage product development and control feedback.
When marketing becomes large scale this company will have a product that has been in actual use and modified based on physician feedback …
Did you notice that PHYSICIANS WERE ONE OF THE EARLY ADOPTEES OF THIS PROGRAM? That tells you a huge amount about the product and its use.
A New Vital Sign to Be Used Along with the EKG
I want to tell you in the most straight forward terms about why this product should be extremely successful — this year — in 2010, and is being used now!
The PD2i® test is painless and functions like a value-added electrocardiogram. Adhesive sensor pads are placed on the skin and for the next twenty minutes the Analyzer records heartbeat information. Exercise is not necessary during the test. This means Vicor has a product that beats the competition and can be used anywhere — particularly in trauma settings.
A simple noninvasive test can within minutes identify patients at risk of sudden cardiac death
An additional use is as a non-invasive test for identifying patients with Diabetic Autonomic Neuropathy. That just jumped the market size for this test exponentially.
As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%.
This represents new vital sign with the ability to actually save lives in both combat and civilian setting. This test is able to identify trauma victims in need of an immediate lifesaving intervention
The test is able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed.
Consistently accurate results can be obtained in just one to two minutes of EKG data in a trauma setting.
Vicor’s Three Products Employing the PD2i™ Nonlinear Algorithm.
- PD2i Analyzer(TM) has FDA 510(k) marketing clearance. It measures Heart Rate Variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes.
- PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
- PD2i CA(TM) (Cardiac Analyzer) identifies patients at risk of sudden cardiac death and is in multiple clinical trials.
Vicor anticipates additional applications employing the PD2i™ nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases.
Business Model
The PD2i Analyzer(TM) represents the genius and ingenuity of Vicor but that is never, never enough. In every post I am going to discuss this amazing business model and management.
Vicor has the business management of their product in high gear. They have FDA clearance to market their product as a measure for Heart Rate Variability AND they have existing CPT codes that physicians can use to bill for the product use. These are crucial to the financial success of the medical break through.
Vicor totally understands recurring revenue is the key. They have adopted the time honored tradition of pricing the device which captures the information at a reasonable level. This is a business model Microsoft uses with the X-Box and Gillette initiated by giving away the razor to sell the razor blade.
Data is transferred over the internet to Vicor and transfered back to Vicor — almost immediately. They physician is able to price the test at a consistent rate and be reimbursed. Vicor is compensated for the use of its PD2i™ nonlinear algorithm.
This happens in biotech. New tests are devised — they become the standard. Companies are launched, shareholders are rewarded and medicine advances, yet again.
Only this time — you are IN THE KNOW.
Thank you,
John Pentony
Publisher, StockGuru.com
Introduction
Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise.
This biotechnology company is focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i™ nonlinear algorithm and software which is:
- Highly accurate
- Provides user friendly data acquisition
- Effective for trauma triage easily deployed in a portable monitor
- Provides a simple noninvasive test for identifying patients at risk of sudden cardiac death
- Provides a simple noninvasive test for identifying patients with Diabetic Autonomic Neuropathy
The advantage of the PD2i™ nonlinear algorithm is that it typically uses recordings made at rest and does not require stress-testing or any active participation from the patient. The test is relatively impervious to data non-stationarities and artifacts, setting it apart from other measures with unparalleled sensitivity.
A large physician shareholder base represents the early adoptees of this Company.
Vicor’s PD2i™ Nonlinear Algorithm is:
- A new vital sign with the ability to actually save lives in both combat and civilian setting
- The PD2i Analyzer™ can capture and display Heart Rate Variability (see defined below) in patients at rest and during paced respiration and controlled exercise.
- Able to identify trauma victims in need of an immediate lifesaving intervention
- Able to be used along with other clinical data to identify patients at risk of sudden cardiac death
- Able to be used along with other clinical data to identify patients who have autonomic dysfunction
- Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed
- Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting
- Not derailed in delivering actionable results by noisy raw EKG data
- Functional in trauma environments and battlefield situations
READ THE FULL STOCKGURU PROFILE HERE:
No comments:
Post a Comment